Bristol-myers Squibb Compnay

Bristol Meyers Squibb Company

Zhaoxing Meng

Ronald J Mattson

John E Macor

Paul Michael Scola

Kap-Sun Yeung

Mark George Saulnier

Katharine A Grant-Young

David Bertil Frennesson

Dalton King

Juliang Zhu

Piyasena Hewawasam

David R Langley

Li-Qiang Sun

Eric Mull

Richard Eric Olson

Tao Wang

Zhongxing Zhang

Lawrence B Snyder

Jason T Goodrich

Kyle E Parcella

Ivar M McDonald

Alan Xiangdong Wang

Timothy P Connolly

Lawrence R Marcin

Ningning Xu

Charles P Sloan

Jonathan L Ditta

Derek John Denhart

Dane M Springer

Leatte R Guernon

Jeffrey A Deskus

Davidb Frennesson

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Compounds useful as immunomodulators

The present disclosure generally relates to compounds of formula (I), wherein R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases. 

1,3-dihydroxy-phenyl derivatives useful as immunomodulators

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. Formula (I): 

Positive allosteric modulators of mGluR2

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. 

Disclosed are compounds, pharmaceutical compositions containing the compounds, methods for using the compounds and processes for making the compounds. More specifically, the disclosure relates to alpha-(N-benzenesulfonamido)cycloalkyl compounds that may inhibit one or both of: (i) the functioning of a &#x3b3;-secretase enzyme; or (ii) the production of &#x3b2;-amyloid. Such compounds may be beneficial in the treatment of Alzheimer's disease and other conditions. Representative compounds have the following formula I: wherein: A, R, and Rare described herein.

Alpha-(N-benzenesulfonamido)cycloalkyl derivatives

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.

Compounds for the treatment of premature ejaculation

Cyclopentyl indole derivatives

Isoxazolinone antibacterial agents

Growing community of inventors

Middletown, CT, United States of America

Zhaoxing Meng